Semaglutide

GLP-1 receptor agonist for metabolic research — supports glucose control and weight-management studies.

Semaglutide is a modern GLP-1 receptor agonist widely studied for type 2 diabetes and body-weight regulation. It mimics the incretin pathway, reduces hepatic glucose output, slows gastric emptying, and increases satiety signaling. Research indicates benefits for glycemic control, fat loss, cardiovascular risk markers, and insulin sensitivity. Supplied as lyophilized powder for subcutaneous reconstitution. For laboratory and research use only — not for human consumption without qualified supervision.